Legend Biotech Corp (LEGN)
40.94
+1.19
(+2.99%)
USD |
NASDAQ |
Nov 22, 16:00
40.95
+0.01
(+0.02%)
After-Hours: 20:00
Legend Biotech Debt to Equity Ratio: 0.2658 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.2658 |
| June 30, 2024 | 0.2516 |
| March 31, 2024 | 0.246 |
| December 31, 2023 | 0.2248 |
| September 30, 2023 | 0.206 |
| June 30, 2023 | 0.1923 |
| March 31, 2023 | 0.407 |
| December 31, 2022 | 0.3506 |
| September 30, 2022 | |
| June 30, 2022 | 0.3363 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.2889 |
| December 31, 2021 | 0.1573 |
| September 30, 2021 | 0.3123 |
| June 30, 2021 | |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
0.407
Maximum
Mar 2023
0.1799
Average
0.2154
Median
Debt to Equity Ratio Benchmarks
| Johnson & Johnson | 0.5096 |
| Ligand Pharmaceuticals Inc | 0.00 |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.9382 |
| IGC Pharma Inc | 0.0183 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.736B |
| Total Liabilities (Quarterly) | 619.72M |
| Shareholders Equity (Quarterly) | 1.116B |
| Current Ratio | 4.984 |
| Net Debt Paydown Yield | -0.06% |